Antibody Mimetics: An Overview

Antibody mimetics are compounds that behave in a similar fashion to antibodies, and bind to specific antigens; however, they are artificial peptides and are not related to antibodies.

Antibodies - By ustas7777777

ustas7777777 | Shutterstock

Why use antibody mimetics?

Although antibodies bind to specific antigens, many antibodies cross-react with other antigens. Thisleads to false positives in techniques using antibodies.

Antibodies are also large and consist of four polypeptide chains: two heavy chains and two light chains, where the heavy chains are connected using disulphide bonds. The large size often poses a problem if they are required to enter cells, or in cases where the antibodies need to deliver drugs, or be incorporated in to biomaterials.

Their shelf-lives are also limited, which can be another problem in remote locations or countries which do not have access to continuous power supply and refrigeration. These issues led scientists to look for or create molecule which performed similar functions to antibodies but could overcome these limitations.

Creating antibody mimetics

The strategies used to create mimetics include site directed mutagenesis and random mutagenesis to create novel proteins that have binding properties. These proteins have greater stability compared to antibodies despite having a simpler structure. Also, they can be tailor-made to have specific properties – greater solubility, protease-resistance, temperature stability, pH stability, and others.

To create antibody mimetics, a defined protein structure scaffold is required where additional modifications, mutations, or insertions can be added without affecting its structure and stability.

Current types of antibody mimetics

Several types of antibody mimetics exist currently and some of them are discussed here.

Affibodies

Affibodies are one of the widely used antibody mimetics, and their protein scaffold is derived from the B-domain of staphylococcal protein A. The B-domain consists of 58 amino acids which form three α helices that bind to IgG.

Since its discovery, several modifications have been added; in one study, the scaffold was modified to improve its thermal and chemical stability. Subsequently, other studies have also improved its affinities and binding properties. Affibodies are smaller in size compared to antibodies, have higher solubility and thermal stability and are cost-effective.

Adectins

Adectins are derived from the extracellular domain of human fibronectin III protein. They have seven β strands that are linked by six loops, and the structure of the β sandwich formed is similar to the variable region of antibodies. This makes adectins a good candidate as an antibody mimetic.

Although adectins have a simpler structure compared to antibodies, their specificity and affinity are similar to antibodies. Adectins have been tested against several ligands, including human vascular endothelial growth factor receptor 2, proprotein convertase subtilisin kexin-9, EGFR, the p19 subunit of interleukin-23, and β-cyclodextrin.

Peptide aptamers and affimers

Peptide aptamers are short peptide sequences that have an inert and rigid scaffold. Affimers – aptamers with improved performance – have been used in several analytical applications, such as ELISA, affinity chromatography, microarrays, immunohistochemistry and others. Recently, affimers have also been designed for a Zika virus antigen. This could lead to the development of a diagnostic tests for the Zika virus, which are loosely based around an ELISA.

Affitins

Affitins are a protein that is a variant of Sac7d, a DNA-binding protein. This protein can bind to DNA and prevent its thermal denaturation. It is derived from thermophilic bacteria called Sulfolobus acidocaldarius.

It had 66 amino acids, an incomplete β barrel structure (two-stranded β-hairpin, three-stranded β-sheet, and a α helix). As they are derived from thermophilic bacteria, they are highly resistant to heat.

Anticalins

Anticalins are proteins with binding properties that have a β barrel structure with eight β strands and one α helix. They have one peptide chain that is 150–190 amino acids long.

Other examples

Apart from these antibody mimetics, there are also avimers, fynomers, armadillo repeat proteins, and knottins. All these different classes of proteins have specific binding properties, and are superior to antibodies in terms of affinity, stability, penetration, and cost-effectiveness.

Further Reading

Last Updated: Nov 23, 2018

Dr. Surat P

Written by

Dr. Surat P

Dr. Surat graduated with a Ph.D. in Cell Biology and Mechanobiology from the Tata Institute of Fundamental Research (Mumbai, India) in 2016. Prior to her Ph.D., Surat studied for a Bachelor of Science (B.Sc.) degree in Zoology, during which she was the recipient of an Indian Academy of Sciences Summer Fellowship to study the proteins involved in AIDs. She produces feature articles on a wide range of topics, such as medical ethics, data manipulation, pseudoscience and superstition, education, and human evolution. She is passionate about science communication and writes articles covering all areas of the life sciences.  

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    P, Surat. (2018, November 23). Antibody Mimetics: An Overview. News-Medical. Retrieved on June 01, 2023 from https://www.news-medical.net/life-sciences/Antibody-Mimetics-An-Overview.aspx.

  • MLA

    P, Surat. "Antibody Mimetics: An Overview". News-Medical. 01 June 2023. <https://www.news-medical.net/life-sciences/Antibody-Mimetics-An-Overview.aspx>.

  • Chicago

    P, Surat. "Antibody Mimetics: An Overview". News-Medical. https://www.news-medical.net/life-sciences/Antibody-Mimetics-An-Overview.aspx. (accessed June 01, 2023).

  • Harvard

    P, Surat. 2018. Antibody Mimetics: An Overview. News-Medical, viewed 01 June 2023, https://www.news-medical.net/life-sciences/Antibody-Mimetics-An-Overview.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like...
Antibody combination strongly protects high-risk people with early COVID-19 symptoms, trial shows